Although coronary artery disease (CAD) is the leading cause of death in type 1 diabetes (T1D), the mechanisms responsible for the greatly increased risk are poorly understood. In particular, the role of glycaemic control is controversial with one study suggesting it predicts CAD mortality but not incidence. In this analysis, of the Pittsburgh Epidemiology of Diabetes Complications study cohort of T1D, we examine whether risk factors differ for CAD morbidity and mortality, with a specific focus on HbA1c and insulin dose. Participants (n=592) were followed for 18 years for incident non-fatal and fatal CAD. Cox stepwise regression was used to determine the independent risk factors for non-fatal and fatal CAD. Mean age and diabetes duration at study baseline were 29 and 20 years, respectively. There were 109 incident non-fatal and 48 fatal CAD events. Baseline HbA 1C was an independent risk factor for fatal CAD, along with duration of diabetes and albuminuria. In contrast, baseline lower insulin dose was strongly predictive of non-fatal CAD, as was lower renal function, higher diastolic blood pressure, and lipids. HbA 1C predicts CAD mortality while lower insulin dose and standard CAD risk factors predict CAD morbidity.
Introduction
Although coronary artery disease (CAD) is the leading cause of death in type 1 diabetes (T1D), the mechanisms responsible for the greatly (up to 10-fold) increased risk are poorly understood. While both insulin excess and deficiency have been implicated, 1,2 standard CAD risk factors, e.g. blood pressure and lipids, are also clearly operational. The role of glycaemic (e.g. HbA
1C
) control however is less clear. On the one hand, a small study of older onset T1D cases, without renal disease, reports a significant association 3 and there is clear evidence that intensive glucose management in the Diabetes Control and Complications Trial (DCCT) was associated with major reductions of cardiovascular disease (CVD) events in an extended follow up. 4 On the other hand, however, three cohort studies, a follow-up of patients from the Hvidore Hospital in Denmark, 5 the Pittsburgh Epidemiology of Diabetes Complications (EDC) study 6 and the EURODIAB study 7 all failed to show a significant and/or independent association. Finally, while the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) has consistently reported a modest association, most recently 8 with morbidity (myocardial infarction) was not significant. 9 This raises the possibility that glycaemia may relate more strongly to CAD mortality than to morbidity. In this analysis, we therefore address, in the Pittsburgh EDC study (for the first time as we have not hitherto had a sufficient number of events), the question of whether risk factors are different for CAD morbidity and mortality, with a specific focus on HbA 1C and insulin dose.
Methods
The study population is the Pittsburgh EDC study, which includes subjects with childhood (< 17 years old) onset T1D diagnosed between 1950 and 1980 at Children's Hospital of Pittsburgh. The 658 subjects participating at baseline were examined between 1986 and 1988 and followed biennially. All study participants provided informed consent and the University of Pittsburgh Institutional Review Board approved the study protocol.
Outcomes were non-fatal CAD or fatal CAD. Non-fatal CAD was defined as myocardial infarction confirmed on medical records or Q-waves (Minnesota codes 1.1 or 1.2), 10 or revascularisation procedures, including coronary artery bypass graft, angioplasty and coronary endarterectomy, or coronary artery stenosis ≥ 50% without revascularisation. All deaths were investigated by obtaining autopsy, coroner, or medical records. Two physicians (TO, JF) classified deaths according to the Diabetes Epidemiology Research International procedures. 11 Those classified as having myocardial infarction or CAD as the underlying cause of death formed the second outcome.
Information was collected by questionnaire concerning demographic characteristics, medical history, Beck Depression Inventory, 12 and health care behaviours, as previously described. 13, 14 A history of smoking was defined as having smoked at least 100 cigarettes in a lifetime. Participants were weighed in light clothing on a balance beam scale. Height was measured using a wall-mounted stadiometer.
Blood samples were assayed for lipids, lipoproteins, haemoglobin (HbA 1 ), creatinine, fibrinogen and white blood cell count (WBC), as previously described. 13 ] + 0.14). Blood pressure was measured by a random-zero sphygmomanometer according to a standardised protocol 15 after a 5-min rest period. Hypertension was defined as a blood pressure of at least 140/90 mmHg or the use of anti-hypertensive medications.
Complications were assessed as previously described 13, 14 and overt nephropathy defined as an albumin excretion rate > 200 μg/min in 2 of 3 timed urine samples. 16 Estimated glomerular filtration rate (eGFR) was based on the Cockcroft-Gault formula. 17 Although we have previously shown differences in CAD risk factors by sex, even though there was no difference in the risk of CAD, 18 formal tests of interaction did not reveal a significant difference between sex and HbA 1C or most other significant univariate predictors of the 18-year incidence of fatal or non-fatal CAD. Nevertheless, as sex interactions with albumin excretion rate (p<0.05) and diastolic blood pressure (p=0.07) were observed for non-fatal CAD, we have chosen to present results overall and gender-specifically. Additionally, approximately 10% of our population (n=66) was under the age of 18 years at baseline. As adolescence is a time of variable change in anthropometric measurements, i.e. waist circumference and body mass index (BMI), as well as hormonal status resulting in increased insulin requirements due to insulin resistance, and as this age group is likely to have the longest event-free follow-up time, the paediatric population was excluded from analyses.
Participants were followed from 1986-1988, when the baseline examinations were conducted, until January 31, 2007 when mortality was censored. Continuous data were compared across groups by the Student's t test. Categorical data were compared across groups by Pearson's χ² test. Kaplan-Meier analyses and univariate Cox proportional hazards models were used to explore the association of HbA 1C and daily insulin dose/kg of body weight with fatal and non-fatal CAD. Multivariable Cox proportional hazards modelling with stepwise selection was used to determine the independent predictors of each of the two outcomes: non-fatal and fatal CAD. Covariates that were univariately significant or of biological plausibility were allowed to enter the model. Given the strong correlation between age and duration (r=0.84) only duration was used in multivariable analyses. Both systolic blood pressure (SBP) and diastolic blood pressure (DBP) were univariately significant predictors of each outcome; however, in separately fitted multivariable models, only DBP was selected as an independent variable. Therefore, since both variables were highly correlated (r=0.70), in multivariable analyses, only DBP was allowed in the models. Models allowed for sex, diabetes duration, insulin dose/kg body weight, HbA 1C , waist circumference, (log) albumin excretion rate (AER), (log) eGFR, DBP, use of hypertension medication, WBC, high density lipoprotein cholesterol (HDLc), non-HDLc, (log) fibrinogen, and a history of smoking. Cox modeling using updated mean variables (the average value of a variable during follow-up) was also conducted. Analyses examining Beck Depression Inventory, and physical activity were limited to smaller populations (n=525 and 550, respectively). AER, eGFR, fibrinogen, the Beck Depression Inventory, score and physical activity were natural logarithmically transformed before analyses. All hazard ratios are reported as per one standard deviation change in the continuous variables, except where stated. The criterion for statistical significance was p<0.05. Statistical analysis was conducted using SAS version 9.1 (Cary, NC, USA).
Results
During 18 years of follow-up (mean=15.0 years), 127 of the 572 participants remaining after exclusions (i.e. 13 with prevalent CAD, 7 individuals with incomplete data, and the 66 aged less than 18 years), had an incident CAD event; 109 of those were non-fatal (22% of men and 16% of women). There were also 128 deaths, 48 due to CAD. For both endpoints (Tables 1 and 2 ), cases were significantly older and of longer diabetes duration, had poorer kidney function (eGFR) and greater kidney damage (AER) and a higher WBC. Cases were also more likely to have hypertension, a worse lipid profile, a history of smoking, marginally lower physical activity levels, a higher Beck Depression Inventory score, or other co-morbid conditions. BMI was not significantly different between cases and non-cases for either non-fatal or fatal CAD. Waist circumference, however, was significantly higher in those subsequently experiencing either a non-fatal or fatal CAD event, but statistical significance disappeared after stratification by sex. A history of severe hypoglycaemia was more common in those who experienced a non-fatal CAD event, while this difference did not exist for fatal CAD. Mean HbA 1C did not differ between non-fatal CAD cases and non-cases (8.9% vs. 8.7%, p=0.25, respectively); however, it was predictive of CAD mortality (9.2% vs. 8.7%, p=0.03). The converse was true for daily insulin dose/kg of body weight. Mean daily insulin dose/kg of body weight at baseline was significantly lower in those who progressed to non-fatal CAD (0.71 vs. 0.78, p=0.009), but not in those who died of CAD (0.77 vs. 0.76, p=0.91). There was no difference by sex. In multivariate analyses (Table 3) , diabetes duration, insulin dose/kg of body weight, eGFR (renal function), DBP, HDLc, non-HDLc, and WBC were significant predictors of the 18-year incidence of non-fatal CAD events. HbA 1C was not. Sex-specific analyses revealed that in men diabetes duration, non-HDLc, and renal function (eGFR), but not damage (AER), were predictive. In females, diabetes duration and non-HDLc were also predictive, but kidney AER = albumin excretion rate; eGFR = estimated glomerular filtration rate; WBC = white blood cell count; SBP = systolic blood pressure; DBP = diastolic blood pressure *Natural logarithmically transformed before analysis **Having smoked at least 100 cigarettes in a lifetime function was not. WBC and DBP were also independent predictors in women. There were forty-eight fatal CAD events, twenty-five (52%) with a prior history of CAD. Significant independent predictors of CAD mortality (Table 3) , such as non-fatal CAD, included diabetes duration and WBC. However, HbA 1C and renal damage (AER) were now also predictive, while daily insulin dose/kg of body weight, blood pressure, lipids, and renal function were not. Sexspecific analyses revealed that diabetes duration, HbA 1C , eGFR (renal function), and WBC were significant predictors in men. For women, the significant predictors were diabetes duration, albumin excretion rate (renal damage), and smoking. When allowed for, neither physical activity nor Beck Depression Inventory score were selected for either outcome either overall or sex-specifically.
Finally, Cox models were repeated using updated means rather than baseline variables and confirmed the above associations, except that HbA1c was also a predictor of nonfatal events (HR=1.18, 1.01-1.38) along with insulin dose (inversely), diabetes duration, AER, DBP, non-HDLc, and WBC. In the fatal CAD model with updated means, blood pressure medication was protective, and HbA 1c , diabetes duration, non-HDLc, and AER remained significant predictors (data not depicted).
Discussion
These data, though generally consistent with our previous reports using combined fatal and non-fatal CAD events, suggest that predictors of these two components of CAD differ significantly. In particular a lower daily insulin dose, but not HbA 1C , independently predicts non-fatal CAD, while HbA 1C , but not insulin dose, predicts fatal CAD. We also confirm that traditional risk factors continue to predict CAD over the long term (18 years) and confirm previous reports that though absolute CAD risk does not vary by gender, CAD risk factors do. 18 
HbA

1C
has previously been shown to predict CAD in T1D by some, 8, 19, 20 but not all, 6, 7, 9 prior studies, as recently reviewed. 21 Since that review, Shankar et al. 8 have reported an update from the WESDR study showing that elevated glycated haemoglobin remains predictive of both CVD mortality and, interestingly, all-cause mortality, a finding also seen in the general population. 22 The current results thus may help, in part, resolve the conflicts between the epidemiologic studies [6] [7] [8] [9] 19 as the EDC study now shows an association with CAD mortality, consistent with WESDR, 8, 20 but not for non-fatal CAD, also consistent with WESDR. 9 The reason why HbA 1C may be more closely related to CAD mortality than to non-fatal CAD is likely to be multifactorial. First, this may be mathematical as all the risk factors examined are closely related and in the time to event analyses, HbA 1C was univariately associated with both outcomes. It is therefore reasonable to conclude that there is a stronger association of HbA 1C with mortality than with morbidity. However, the multivariable models were stable and multicollinearity was not strong. Secondly, as HbA 1C is a strong predictor of microvascular complications, 23, 24 this will increase the risk of significant co-morbidities (e.g. renal disease), which may increase case fatality. This is, however, unlikely the full explanation as such complications, particularly renal disease, also increase the risk of non-fatal CAD (Table 1) .
A third likely explanation may be that inadequate glycaemic control at the time of an acute coronary syndrome (ACS) may jeopardise the injured myocardium and thus lead to greater mortality (case fatality). The first DIGAMI study 25 and other studies 26, 27 that show better outcomes in patients with ACS who are in better glycaemic control would be consistent with this argument, although in the current study we do not have glucose values available from the time of event.
A failure of baseline HbA 1C to predict CAD overall (i.e. combined fatal and non-fatal CAD) has been a consistent finding in our population and has led to the proposal that part of the explanation maybe that hyperglycaemia, which leads to advanced glycation end product (AGE) formation and protein cross-linking, may yield a more 'stable' type of atherosclerosis, which would be less likely to rupture and cause an ACS. 21 This would help explain a weak relationship with CAD events despite their being increased atherosclerosis in T1D. The extensive evidence for this 'glucose stabilisation' theory has also recently been reviewed. 21 The current analyses extend these observations further and suggest that A1c (glycemic control) may influence the natural course of CAD events in addition to their outcome.
Another important finding in the current analysis is that insulin dose is closely, and inversely, related to non-fatal CAD (but shows no association with mortality). This observation is also consistent with the hypothesis that adequate insulin dosage is critical to avoid accelerated atherosclerosis and further suggests that possibly some of the contribution of better 'glycaemic' levels, in those studies with a strong association, may result from better insulin dosage and regulation in addition to lower glycaemic exposure alone. Unfortunately, with the exception of Rossing et al., 5 insulin dose has not been reported in these epidemiologic studies, and even in Rossing's study, was not used in multivariable models.
Daily insulin dose/kg of body weight may therefore be more closely related to non-fatal CAD than HbA 1C as it may be a better measure of overall insulin mediated glucose homeostasis and metabolic regulation than HbA 1C , which NS = not selected; AER = albumin excretion rate; eGFR = estimated glomerular filtration rate; DBP = diastolic blood pressure; SBP = systolic blood pressure; HDLc = high-density lipoprotein cholesterol; WBC = white blood cell count * Natural logarithmically transformed before analyses Models allowed for sex, diabetes duration, insulin dose/kg body weight, HbA1C, waist circumference, (log) AER, (log) eGFR, DBP, use of hypertension medication, WBC, HDLc, non-HDLc, (log) fibrinogen and a history of smoking measures average blood glucose, capturing both hypoglycaemia and hyperglycaemia, over approximately a three-month time span. It is possible that non-fatal CAD cases had greater glucose variability despite having similar average glucose compared with non-cases. Interestingly, in the current analyses severe hypoglycaemia (i.e. resulting in unconsciousness) was predictive of non-fatal CAD (HR=1.8, p=0.004), but not fatal CAD (HR=0.94, p=0.85) until adjusted for diabetes duration, suggesting greater excursions to the lower range at least. Glucose instability, or oscillations, have been shown to be more highly associated with oxidative stress and angiogenesis than sustained hyperglycaemia. 28 The dramatic findings of the DCCT/EDIC study, 4 showing a 57% reduction of non-fatal myocardial infarction, stroke and CVD death in the former intensively treated group, would initially appear to be at variance with our results, for the positive findings are largely based on nonfatal events for which the current study suggests a weaker glycaemic association. There are insufficient fatal cases (three in the intensive and four in the conventional groups) in DCCT/EDIC to permit a similar analysis to that presented here. However, at this time it is unclear how this intensive therapy effect is mediated, as full risk factor modelling has not been reported and thus it is possible that some of the benefit of intensive management is related to nonglycaemic effects (e.g. multiple insulin dose regimen, per se), as well as to level of glycaemic control.
We have also demonstrated that the traditional cardiovascular disease risk factors are, in general, predictive of CAD in T1D, despite the differences discussed above. Dyslipidaemia and blood pressure, predictive of cardiovascular disease in the general population, were also predictive of CAD in our T1D population. As Shankar et al. 8 point out, proteinuria and dyslipidaemia are consequences of hyperglycaemia and therefore may be intermediates in the causal pathway between hyperglycaemia and mortality. Interestingly, age-adjusted HbA 1C was predictive of non-fatal CAD events in our population until the association was adjusted for non-HDL cholesterol, which would be consistent with low insulin dosage being the underlying derangement resulting in both elevated HDL and non-HDL cholesterol and high blood glucose. Change over time may also be critical as evidenced by our time dependent, i.e. updated mean, modeling, where HbA1c was also predictive of morbidity along with lower insulin dose (although, like at baseline, insulin dose was not predictive of mortality).
Consistent with previous findings in T1D, 4, 18 neither fatal nor non-fatal CAD risk differed by gender. We did, however, find gender differences in risk factors, consistent with previous findings in this population 18 . These sex differences are important to confirm in other populations as they may significantly affect the design of optimal intervention strategies.
A limitation of this study is that participants have not been followed from diagnosis, which may have been as early as 1950. There is therefore a considerable early mortality/survival effect. Further analyses will address this when event numbers permit.
Conclusions
In conclusion, the current data further confirm the complexity of the associations of glycaemic control and diabetes management with cardiovascular disease. The observations that HbA 1C more strongly predicts CAD mortality than morbidity, and insulin dose relates more strongly to CAD morbidity than mortality, may provide important insights into our understanding of the aetiology of CAD in T1D. Further evaluation of these observations may lead to important clinical implications. These include that the closer relationship of HbA 1C with mortality likely reflects, in part, the benefit of good glycaemic control at the time of myocardial insult thus enabling more efficient and less toxic myocardial metabolism. The converse observation that a low insulin dose predicts non-fatal events should also help allay fears that insulin itself is strongly atherogenic and encourage clinicians to use adequate insulin dosage to achieve good control. Our findings thus underscore the importance of adequate insulin dosage, as well as the management of all standard risk factors for CAD, including blood pressure and lipids, in T1D.
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